Acute infection with HCV leads to chronic infection or spontaneous clearance, making it a model chronic infection. In the previous grant cycle, we have made important contributions to defining the defects in host innate and adaptive immunity that contribute to the remarkable predilection to chronicity of HCV infection. We and others have established that a polymorphism near the IL28B (1FNA.3) gene is profoundly associated with spontaneous HCV clearance. However, until recently, studies of the predominant SNPs failed to uncover a functional polymorphism. Recently, a dinucleotide polymorphism upstream of IFNA,3 was found to create (AG) or disrupt (TT) an open reading frame in a new locus, 1FNA.4. The finding that the unfavorable allele is associated with production of 1FNX,4 raises the distinct possibility that IFNA,4 production in response to viral infection has undesirable consequences for chronicity, including chronic stimulation of ISGs. In contrast, another study found that PBMCs from patients harboring the unfavorable AG exhibited lower poly(l:C)-induced IFNXS and IP-10 expression than those harboring TT. The exciting finding of a functional polymorphism now enables the mechanistic dissection of the effect of genotype on IFN and ISG Induction in both hepatocytes and PBMCs. Recent data from mouse models of LCMV have shown that type I IFN released during chronic infection induces ISGs that through suppressive cytokines, contribute to virusspecific T cell hypofunction. Strikingly, blockade of type I IFN signaling during the chronic phase restores T cell function and produces a paradoxical antiviral effect. These findings can now be readily tested in the paradigm human chronic infection model, HCV. We will therefore test the overall hypothesis that HCV associated type I IFN signaling exerts a long term Immune suppressive effect that can be partially to completely reversed by removing virus. With new direct acting antiviral (DAA) combinations promising high viral cure rates and independence IFN treatment, we now have the unprecedented opportunity to evaluate the effect of DAA-mediated cure on recovery of these impaired functions. Project 1 Aims: (1). Characterize alterations in the type I ISG response, cytokine and APC environment during DAA-mediated viral cure;(2) Evaluate the contribution of a functional SNP near the IFN Lamda3/IFN Lamda4 locus to chronic HCV and to immune recovery with DAA-mediated viral cure (genotype-phenotype correlation). We will use a unique cohort of patients undergoing DAA therapy and comprehensively collect immune samples to support these Aims.

Public Health Relevance

HCV chronically infects over 185 million persons. The basis for HCV's chronicity and its recalcitrance to immune control is not well understood, but may be the product of excess induction of interferon related programs that cause impaired viral immunity. We will exploit the availability of potent, IFN-free antiviral therapy for HCV to evaluate the hypothesis that viral clearance partially but may not completely reverse these immune defects. This study will have implications for reinfection risk, vaccine and treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082630-06
Application #
8726061
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
$382,133
Indirect Cost
$106,386
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Rowe, Ian A; Tully, Damien C; Armstrong, Matthew J et al. (2016) Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 22:287-97
Fergusson, J R; Hühn, M H; Swadling, L et al. (2016) CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunol 9:401-13
Attanasio, John; Wherry, E John (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity 44:1052-68
Llibre, Alba; López-Macías, Constantino; Marafioti, Teresa et al. (2016) LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. J Immunol 196:2085-94
Kurioka, Ayako; Walker, Lucy J; Klenerman, Paul et al. (2016) MAIT cells: new guardians of the liver. Clin Transl Immunology 5:e98
van Wilgenburg, Bonnie; Scherwitzl, Iris; Hutchinson, Edward C et al. (2016) MAIT cells are activated during human viral infections. Nat Commun 7:11653
Jeffery, Hannah C; van Wilgenburg, Bonnie; Kurioka, Ayako et al. (2016) Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol 64:1118-27
Kelly, Christabel; Swadling, Leo; Capone, Stefania et al. (2016) Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 63:1455-70
Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian et al. (2016) HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep 6:22487
Swadling, Leo; Halliday, John; Kelly, Christabel et al. (2016) Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel) 4:

Showing the most recent 10 out of 128 publications